Panacea Biotec on Thursday announced the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAlI, a single-dose live-attenuated tetravalent vaccine.

According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and we must have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions.

The shares are trading at a day's high of Rs 198.15, rising up to 4.98 per cent.